It’s time for a greater role for pharmacists in asthma management
I’ve returned from a Saturday morning in community pharmacy practice and am reflecting on the number of patients I saw with asthma. I checked...
Beyond politics; patient groups and the art of influence
“What is a patient group?”, a friend of mine enquired during one of our recent regular political discussions. It struck me afterwards that given...
The real cost of over the counter prescriptions
NHS England recently published its guidance for CCGs on the over the counter (OTC) items which should not be routinely prescribed in primary care...
David wants understanding between NHS & industry
Not who you say I am:
Pharma companies need to be clear who they’re talking to and why they’re talking to them. Last week a pharma...
Two takes: Bad habits – help or hindrance?
In this month’s emotive opinion battle, we ask two healthcare professionals if we should be encouraging patients to evaluate their lifestyle choices, or are...
Pharmacists are the last step between HCPs and patients
Having the right medicine at the right time and administered in the right way can be the difference between that patient continuing their treatment...
AI is launching healthcare into the future
With tales of Victorian era conditions on hospital wards, chronic ambulance queues and surgery delays reminiscent of the NHS’s nadir in the early 1990s,...
Does a pharmacy career appeal to young people?
For pharmacy graduates forcing doors open is essential. Over 30 years ago I made the decision to study pharmacy at Nottingham University, with little understanding...
Tracking progress of the Rare Disease Strategy
February’s magazine focused on rare diseases, but how can implementation plans for the Rare Disease Strategy be properly monitored? The Rare Disease Strategy implementation plans...
Outcome-based contracts for medicines: What’s the deal?
Outcome-based contracts for medicines – is there enough financial headroom to attract pharma? In the January and February issues of Pf Magazine we discussed the...
Latest articles
IMBRUVICA® misses primary endpoint in pancreatic cancer trial
AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer. AbbVie, a research-based global biopharmaceutical company,...
Star Europe’s Amsterdam office off to positive start
Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
EC approves Vertex’s ORKAMBI® for cystic fibrosis patients
Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients. The European Commission has granted approval...